Breaking News

Tweet TWEET

Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR Antagonist IMO-8400 for the Treatment of Autoimmune

  Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR
  Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013

FOCIS 2013

Business Wire

CAMBRIDGE, Mass. -- June 21, 2013

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will
present positive Phase 1 trial results on IMO-8400, a selective inhibitor of
Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate for the treatment
of autoimmune diseases, at the 13^th Annual Meeting of the Federation of
Clinical Immunology Societies (FOCIS), June 27-30, 2013, in Boston, MA.

Details of the presentation are as follows:

                   
Date:                  Saturday, June 29, 2013
Time:                  6:30-7:45pm ET
Location:              Commonwealth Hall, The Boston Seaport Hotel
Abstract Number:       S.85
Title:                 Phase 1 clinical trial of IMO-8400, an antagonist of
                       Toll-like receptors 7, 8 and 9
                       

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug
discovery platform to create immunomodulatory drug candidates and has a
clinical development program in autoimmune diseases. Additionally, Idera has a
collaboration with Merck & Co. for the use of TLR-targeted candidates as
vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. For
more information, visit http://www.iderapharma.com.

Contact:

Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
larcudi@iderapharma.com